Evidence map›Paper›PMID 26261583›Full record

ArticleInternational journal of clinical and experimental pathology2015

PinX1 is up-regulated and associated with poor patients' survival in gliomas.

Jin Bai, Yan-Su Chen, Peng-Jin Mei, Qing-Hua Liu, Ying Du, Jun-Nian Zheng

Open access · greenAbstract read
In one paragraph

Article in International journal of clinical and experimental pathology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Prognostic and Clinicopathological Value ofBioMed research international · 2018
    Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Jin BaiJiangsu Center for The Collaboration and Innovation of Cancer Biotherapy, Cancer Institute, Xuzhou Medical College Xuzhou 221002, Jiangsu Province, China.
Yan-Su ChenJiangsu Center for The Collaboration and Innovation of Cancer Biotherapy, Cancer Institute, Xuzhou Medical College Xuzhou 221002, Jiangsu Province, China ; School of Public Health, Xuzhou Medical College Xuzhou 221002, Jiangsu Province, China.
Peng-Jin MeiJiangsu Center for The Collaboration and Innovation of Cancer Biotherapy, Cancer Institute, Xuzhou Medical College Xuzhou 221002, Jiangsu Province, China ; Department of Neurosurgery, The Affiliated Hospital of Xuzhou Medical College Xuzhou 221002, Jiangsu Province, China.
Qing-Hua LiuJiangsu Center for The Collaboration and Innovation of Cancer Biotherapy, Cancer Institute, Xuzhou Medical College Xuzhou 221002, Jiangsu Province, China ; Department of Pathology, Xuzhou Medical College Xuzhou 221002, Jiangsu Province, China.
Ying DuJiangsu Center for The Collaboration and Innovation of Cancer Biotherapy, Cancer Institute, Xuzhou Medical College Xuzhou 221002, Jiangsu Province, China.
Jun-Nian ZhengJiangsu Center for The Collaboration and Innovation of Cancer Biotherapy, Cancer Institute, Xuzhou Medical College Xuzhou 221002, Jiangsu Province, China.
Xuzhou Medical College · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PinX1, a conserved nuclear protein, could maintain telomere integrity and plays an important role in regulating telomerase activity. It has been reported that the expression of PinX1 is down-regulated in some cancer and associated with cancer prognosis. However, the value of PinX1 in gliomas has not been studied. In this study, two independent retrospective gliomas cohorts with the corresponding gliomas tissue microarrays (TMAs) were established to detect the expression level of PinX1 and the correlation of PinX1 expression with the clinicopathological features and the patients' survival. Compared with non-cancerous brain tissues, PinX1 protein levels were remarkably up-regulated in gliomas (P = 0.001), and further increased from benign gliomas tissues to malignant gliomas tissues (P = 0.090). Moreover, high PinX1 expression was significantly positively associated with gliomas WHO grade in the training set (P = 0.019) and the validation set (P = 0.037). High PinX1 expression significantly correlated with a worse 5-year overall (P = 0.016) and disease-specific survival (P = 0.026). Simultaneously, the multivariate COX regression analysis showed that PinX1 was an independent unfavorable prognostic factor for 5-year overall survival (hazard ratio (HR) = 2.078, P = 0.015) and disease-specific survival (HR = 2.429, P = 0.012) after adjusting with age, sex and WHO grade in gliomas. In conclusion, PinX1 expression may serve as a prognostic and predictive biomarker for gliomas.

Indexed as

Biomarkers, TumorBrain NeoplasmsCell Cycle ProteinsChi-Square DistributionDisease-Free SurvivalFemaleGliomaHumansImmunohistochemistryKaplan-Meier EstimateMaleMiddle AgedMultivariate AnalysisNeoplasm GradingPredictive Value of TestsProportional Hazards ModelsBiomarkers, TumorCell Cycle ProteinsPINX1 protein, humanTumor Suppressor ProteinsgliomasPinX1prognosistissue microarrayWHO grade

Identifiers

PMID26261583
PMCPMC4525917
OpenAlexW2417791008

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.